文献速递主动脉疾病外周动脉疾病

布鲁菌相关主动脉-髂动脉瘤腔内修复术后纤维蛋白封闭剂联合庆大霉素瘤囊填充的结局:一项回顾性单中心研究

The Outcome of Sac Filling With Fibrin Sealant and Gentamicin After Endovascular Aortic Repair of Brucella-Related Aorto-Iliac Artery Aneurysms: A Retrospective Single-Center Study.
PubMed 文献 · J Endovasc Ther · 2023-11-07

本研究回顾性分析2019年3月至2022年9月单中心14例布鲁菌相关主动脉-髂动脉瘤患者,在腔内主动脉修复(EVAR)后行纤维蛋白封闭剂(FS)联合庆大霉素瘤囊填充。随访中位15.0个月,瘤囊最大直径显著缩小,无内漏、移植物感染或感染相关死亡,结论认为该辅助方法可能有效控制假性动脉瘤感染和破裂。

要点

  • EVAR后FS联合庆大霉素瘤囊填充,围手术期及随访无内漏、血管移植物感染或感染相关死亡。
  • 随访中位15.0个月,主动脉-髂动脉瘤囊绝对和矢状最大直径均较术前显著缩小(P<.001)。
  • 作者认为该靶向给药方式可能有效控制布鲁菌相关动脉瘤感染和破裂,但仍需进一步评估。

核心结论

  • EVAR辅助FS联合庆大霉素瘤囊填充,靶向递药至布鲁菌相关主动脉-髂动脉瘤感染灶,可能是控制假性动脉瘤感染和破裂的有效方案。
  • 作者认为该方式是有吸引力的治疗选择,可摆脱长期依赖抗生素,但仍需进一步评估。

研究设计与样本

  • 回顾性单中心研究,纳入2019年3月至2022年9月接受EVAR后FS联合庆大霉素瘤囊填充的布鲁菌相关主动脉-髂动脉瘤患者14例。
  • 术前及瘤囊填充后使用预载导管评估瘤囊血栓形成和内漏,以监测即刻修复结果。
  • 短期至中期结局通过血管移植物感染(VGI)发生率、全因死亡率、最大动脉瘤直径、瘤囊血栓形成及其他不良事件评估。

主要发现

  • 14例患者中,1例围手术期死于心肌梗死,术后全因死亡率为7.1%(1/14)。
  • 所有患者术后接受抗布鲁菌药物治疗,中位6.0个月(范围3-12个月)。
  • 中位随访15.0个月(范围0.5-36个月)期间,主动脉-髂动脉瘤囊绝对最大直径从术前46.3±17.0 mm缩小至27.2±16.3 mm(P<.001),矢状最大直径从39.2±13.1 mm缩小至24.0±13.8 mm(P<.001)。
  • 2例患者术后假性动脉瘤消失;1例再次干预行双侧股动脉旁路手术。
  • 围手术期及随访期间无过敏反应、肾毒性、内漏、复发、VGI、主动脉相关或感染相关死亡。

临床怎么用

  • 作者认为,EVAR后FS联合庆大霉素瘤囊填充并靶向递药至感染灶,可能是控制布鲁菌相关主动脉-髂动脉瘤感染和破裂的有效方案。
  • 作者认为该方式是有吸引力的治疗选择,可摆脱长期依赖抗生素,但仍需进一步评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to analyze the experience of our center and assess the efficacy of sac filling with fibrin sealant (FS) and gentamicin after endovascular aortic repair (EVAR) in patients with Brucella-related aorto-iliac artery aneurysms. MATERIALS AND METHODS: All patients who received sac filling with FS and gentamicin after EVAR for Brucella-related aorto-iliac artery aneurysms between March 2019 and September 2022 were reviewed. Before and after sac filling with FS and gentamicin, aneurysm sac thrombosis and endoleak were evaluated using a preloaded catheter to monitor immediate repair outcome. Short- to mid-term outcomes were assessed by the incidence of vascular graft infection (VGI), all-cause mortality, maximum aneurysm diameter, aneurysm sac thrombosis, and other adverse events. RESULTS: There were 14 patients with Brucella-related aorto-iliac artery aneurysms who underwent sac filling with FS and gentamicin after EVAR. Perioperative death due to myocardial infarction in 1 patient resulted in a postoperative all-cause mortality rate of 7.1% (1/14). All patients received anti-Brucella drugs for a median of 6.0 (range: 3-12) months postoperatively. During a median follow-up period of 15.0 (range 0.5-36) months, the absolute and sagittal maximum diameters of the aorto-iliac aneurysm sac were significantly smaller than preoperation (from 46.3 ± 17.0 to 27.2 ± 16.3 mm, P<.001, and from 39.2 ± 13.1 to 24.0 ± 13.8 mm, P<.001). Two of these patients had a postoperative disappearance of the pseudoaneurysm. One patient was reintervened for bilateral femoral artery bypass surgery. Except for sac filling with gentamicin, all patients received anti-brucella medication for a median of 6.0 (range: 3-12) months. There were no allergic reactions, nephrotoxicity, endoleak, recurrence, VGI, aorta-related or infection-related deaths during the perioperative period and follow-up. CONCLUSIONS: Sac filling with FS and gentamicin adjunctive to EVAR, with targeted drug delivery to the sites of Brucella-related aorto-iliac artery aneurysm infection lesions, may be an effective solution to control pseudoaneurysm infection and rupture.Clinical ImpactPrevious Brucella-associated aorto-iliac artery aneurysms have been limited to case reports. This study significantly increased the number of Brucella-associated aorto-iliac aneurysms by 19.7% (14/71) and extended the follow-up to 3 years. In this retrospective study of 14 patients with Brucella-associated aorto-iliac aneurysms treated endovascularly with fibrin sealant and gentamicin for sac filling and targeted administration to infection-related aneurysms, there were no aneurysm-related deaths or infection-related complications and may be an effective solution for controlling aneurysm infection and rupture. And, this approach is an attractive treatment for moving away from long-term dependence on antibiotics but still needs further evaluation.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. He Z, Du X, Liu P, et al. The Outcome of Sac Filling With Fibrin Sealant and Gentamicin After Endovascular Aortic Repair of Brucella-Related Aorto-Iliac Artery Aneurysms: A Retrospective Single-Center Study. J Endovasc Ther. 2023. PMID: 37933541. doi:10.1177/15266028231209943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。